Rx-Genes
Treatment Guidance at the Point of Care

Disease

CFHR1 associated susceptibility to atypical hemolytic uremic syndrome (CFH/CFHR1 hybrid allele, CFHR1/CFH hybrid allele, CFHR1/CFHR4 deletion, CFHR3/CFHR1 deletion)[1, 2]

Gene

CFHR1

Inheritance	AR and AD
Current Treatments	Eculizumab, Ravulizumab, Plasma infusion or exchange
Evidence for Treatment	guideline[3]
Non-Molecular Testing Availability	no
Disease Frequency (per 100,000)	0.2[4]
Genes Included in Disease Frequency	C3, CFH, CFI, THBD, CD46, CFB, CFHR1
Experimental / Investigational Therapies	https://clinicaltrials.gov/ct2/results?cond=Atypical+Hemolytic+Uremic+Syndrome&term=&cntry=&state=&

References

[1] https://www.ncbi.nlm.nih.gov/books/NBK1367/

[2] https://pubmed.ncbi.nlm.nih.gov/33048203/

[3] https://pubmed.ncbi.nlm.nih.gov/31935318/

[4] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3198674/